NLS Pharma - NLSP Enterprise Value-to-Sales Ratio

NLS Pharma (NLSP) - corporate logo

NLS Pharmaceutics AG (NLSP) develops innovative treatments for ADHD and narcolepsy. The EV/Sales multiple history illustrates the business valuation trend, with the current figure standing at . The company's strategy relies on the long-term expansion of its presence in the rare sleep disorders niche. Scaling potential is based on securing patents that ensure high margins during global sales.

NLS Pharmaceutics Ltd. (NLSP): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

NLSP (NLS Pharmaceutics Ltd.): analytical breakdowns and indicator data

Fundamental valuation:NLS Pharma NLSP
Flagship merchandise of NLS Pharmaceutics

A conservative investor assesses the fundamental stability of an asset through the Enterprise Value to Sales (EV/Sales) ratio, excluding the impact of debt load. By analyzing the change in enterprise value relative to revenue, one can determine the extent to which the market valuation of NLS Pharmaceutics AG (NLSP) aligns with the potential of its monopoly ADHD treatments to avoid overpaying for inflated expectations regarding cognitive innovations.